Natalie K. Rutherford
Newcastle, NSW, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Utility of serum blood ketone levels and other risk factors for inadequate myocardial glucose suppression ketogenic FDG-PET/CT: a prospective and retrospective cohort study.
Journal: Annals of nuclear medicine
Published: October 03, 2025
Prognostic Value of Combined FDG PET and MRI Analysis of Cervical Cancer: A Systematic Review and Meta-Analysis.
Journal: Journal of medical radiation sciences
Published: August 03, 2025
Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial.
Journal: The Lancet. Oncology
Published: November 29, 2024
Baseline Nodal Status on 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Intermediate- to High-risk Prostate Cancer Is Prognostic for Treatment Failure: Follow-up of the proPSMA Trial.
Journal: European urology oncology
Published: July 20, 2024
[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial.
Journal: The Lancet. Oncology
Published: January 14, 2024
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial.
Journal: The Lancet. Oncology
Published: August 30, 2023
Ventilation Heterogeneity Is a Treatable Trait in Severe Asthma.
Journal: The journal of allergy and clinical immunology. In practice
Published: July 12, 2023
Regional changes with global brain hypometabolism indicates a physiological triage phenomenon and can explain shared pathophysiological events in Alzheimer's & small vessel diseases and delirium.
Journal: American journal of nuclear medicine and molecular imaging
Published: August 29, 2021
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.
Journal: Lancet (London, England)
Published: December 22, 2020
Imaging for precision medicine: can V-P SPECT measure mepolizumab response in asthma?
Journal: Respirology case reports
Published: July 08, 2020
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study.
Journal: Lancet (London, England)
Published: January 23, 2020
PSMA-PET guided dose-escalated volumetric arc therapy (VMAT) for newly diagnosed lymph node positive prostate cancer: Efficacy and toxicity outcomes at two years.
Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published: May 28, 2019
Last Updated: 09/26/2026